Service

AABB Cell and Gene Therapy Pharmacy Accreditation Consulting

AABB Cell and Gene Therapy Pharmacy accreditation is AABB's program for U.S. hospital and retail specialty pharmacies that receive, store, handle and dispense FDA-approved cell and gene therapy (CGT) products, assessed against the AABB Cell and Gene Therapy Standards for Pharmacy, 1st edition. This service is for pharmacy quality leaders adding CGT handling or preparing for AABB's assessment. Integral Healthcare Solutions (IHS) builds the quality-system documents and evidence plan for the accreditation; your pharmacists approve handling.

Last reviewed: October 2026. AABB's standards, accreditation process, CGT pharmacy, activities and fee pages checked on October 3, 2026.

What is AABB Cell and Gene Therapy Pharmacy accreditation?

The governing text is the AABB Cell and Gene Therapy Standards for Pharmacy. AABB's standards page shows the 1st edition as the current one, effective October 1, 2025, with a 24-month revision cycle (AABB CGT Standards for Pharmacy, page opened October 3, 2026).

For scoping, the useful line is where pharmacy handling ends. AABB's standards page aims the standards at pharmacy-side receipt, storage, handling and dispensing of approved CGT products and biotherapies, and places collection of starting material, manufacturing and clinical administration outside them (AABB CGT Standards for Pharmacy, page opened October 3, 2026).

AABB's accreditation activities list (Version 3, effective April 2, 2026) names a Cell and Gene Therapy Activity for Pharmacy, which is a facility that takes in, stores, handles or dispenses FDA-licensed cell and gene therapy products through its pharmacy (AABB Accreditation Activities, page opened October 3, 2026).

The process runs in two phases, a self-assessment and then an on-site assessment, whether the pharmacy is applying for the first time or adding an activity (AABB Accreditation Process, page opened October 3, 2026). On AABB's CGT pharmacy page, the pharmacy works through its requirements in APEX, the portal AABB uses for accreditation, and then books an on-site visit with an AABB assessor, whose task is to test written procedures against the standards and see whether staff practice matches them (AABB CGT pharmacy accreditation, page opened October 3, 2026). If the assessor finds non-conformances, the pharmacy prepares a Corrective Action Plan and completes a Post-Assessment Questionnaire (AABB).

Who needs it and what triggers it

How IHS helps

IHS works from your pharmacy's purchased copy of the AABB Cell and Gene Therapy Standards for Pharmacy. The process:

  1. Gap assessment. A quality-system crosswalk that compares your current pharmacy procedures with each standard.
  2. Responsibility map. Who does what for receipt, storage, handling, dispensing and the hand-off to the administering clinical team, since administration sits outside the standards.
  3. Document and evidence mapping. Each standard tied to the policy, process, procedure or record that shows it is met, set up as the evidence plan for the APEX self-assessment.
  4. Drafting. IHS drafts controlled documents, deviation records and handling procedures for your CGT pharmacists to review and approve.
  5. Mock review. A review against the standards before AABB's on-site visit, listing what is missing.
  6. Readiness support. If the assessment produces non-conformances, IHS drafts the corrective action plan for your pharmacy to review and submit.

IHS draws on its URAC specialty pharmacy accreditation process for the pharmacy operations side. See the wider accreditation consulting practice for related programs.

What you supply: the standards, current pharmacy procedures, the manufacturers' handling instructions, and CGT pharmacists who approve all handling and validation content. Your pharmacy submits the application and completes the self-assessment in APEX.

The limit: product handling validation is technical work that stays with your pharmacists. IHS works from the published standards and AABB's public process pages; the accreditation decision is AABB's.

What to have ready

Printable version of this checklist (PDF)

How it compares

The table sets out the options the sources describe. Which one fits depends on your pharmacy's activities and its obligations.

OptionWhat the sources say
AABB CGT Pharmacy accreditationStandards aimed at pharmacy-side receipt, storage, handling and dispensing of approved CGT products (AABB).
URAC or ACHC specialty pharmacy accreditationGeneral specialty pharmacy programs. This page does not summarize their requirements. AABB's own page treats CGT handling as its own accreditation track, separate from general pharmacy programs (AABB).
FACT accreditationFACT describes itself as an accreditor of cellular therapy programs (FACT, page opened October 3, 2026). The sources reviewed do not say whether FACT accredits pharmacies dispensing licensed CGT products.
AABB Standards for Cellular Therapy ServicesFor facilities that obtain, process, store or distribute cellular therapy products (AABB Biotherapies). For pharmacies, AABB's path is the CGT Pharmacy standards.
No accreditationThe sources reviewed do not say whether any manufacturer or payer requires AABB CGT accreditation.

What it costs

AABB publishes its institutional dues and fees in a one-page schedule (AABB institutional dues and fees, page opened October 3, 2026). For cell and gene therapy pharmacy accreditation, the schedule lists these kinds of charges:

AABB sells the Cell and Gene Therapy Standards for Pharmacy separately in print, portal and bundled versions, with member prices below list (AABB Purchase Standards, page opened October 3, 2026).

These are AABB's charges, not a total cost and not IHS fees. Verify current fees with AABB. Our AABB fee guide explains what AABB charges for and how membership fits. IHS scopes each engagement after a free introductory call.

What this is not

Frequently asked questions

What is AABB Cell and Gene Therapy Pharmacy accreditation?

It is AABB accreditation for pharmacies that receive, handle, store and dispense FDA-licensed cell and gene therapy products. The pharmacy is assessed against the AABB Cell and Gene Therapy Standards for Pharmacy, 1st edition, effective October 1, 2025.

Which pharmacies are eligible: hospital, health-system or retail specialty pharmacies?

AABB aims the program at U.S.-based hospital and retail specialty pharmacies that dispense FDA-approved CGT products. Separately, AABB's general process page sets a minimum of 6 months of operation in the activity before the initial process can begin.

What do the AABB Cell and Gene Therapy Standards for Pharmacy cover, and what do they leave out?

They address what a pharmacy does with approved CGT products and biotherapies once they arrive: receiving, storing, handling and dispensing. According to AABB's standards page, work before or after the pharmacy, meaning collecting starting material, manufacturing the product and administering it clinically, falls outside them.

How long does AABB CGT pharmacy accreditation take?

AABB's process page puts the usual time for both phases at one to two years. After accreditation, the on-site assessment repeats every two years.

How much does AABB CGT pharmacy accreditation cost, including membership and assessment fees?

AABB's fee schedule lists the parts: basic membership, an application fee for new members, a yearly cell and gene therapy volume charge, the Cell and Gene Therapy activity fee and an added accreditation fee for activities assessed with a lead assessor. Extra charges may apply for more than one site. The amounts are in AABB's schedule, linked in the cost section above. Verify current fees with AABB.

What happens during the APEX self-assessment and the on-site assessment?

Your pharmacy works through the CGT Standards requirements in APEX, the portal AABB uses for accreditation. Once AABB reviews and approves that work, the process moves to an on-site assessment, where the assessor compares your written procedures with the standards and looks for evidence that staff work from them. Any non-conformances lead to a Corrective Action Plan and a Post-Assessment Questionnaire.

Do manufacturers require AABB CGT accreditation before a pharmacy can dispense their product?

The AABB pages reviewed for this page do not say, and no manufacturer or payer source was reviewed. Check each manufacturer's own site requirements.

How does AABB CGT pharmacy accreditation differ from URAC or ACHC specialty pharmacy accreditation?

The AABB program is built on standards written for CGT receipt, storage, handling and dispensing. AABB describes the program as a separate track for CGT products, apart from general pharmacy accreditation. This page does not summarize URAC or ACHC requirements.

Recent changes

  • CMS Proposes Reforms to Strengthen Transparency & Affordability in Medicare Advantage and Part D

    · Centers for Medicare & Medicaid Services

    Centers for Medicare & Medicaid Services states: “CMS issued a proposed rule that would improve the accuracy of provider directories for Medicare Advantage plans, establish transparency and compensation requirements for Pharmacy Benefit Managers, and deliver enhanced cost-saving protections for low-income Medicare beneficiaries.”

    Checked

  • Medicare Program; Implementation of Sections 6219, 6220, and 6224 of the Consolidated Appropriations Act, 2026

    · Centers for Medicare & Medicaid Services

    Full title: Medicare Program; Implementation of Sections 6219, 6220, and 6224 of the Consolidated Appropriations Act, 2026 (Proposed rule; FR Doc. 2026-21420)

    Centers for Medicare & Medicaid Services states: “This proposed rule would implement section 6219 (Adjustments to Medicare Part D Cost-Sharing Reductions for Low-Income Individuals), section 6220 (Requiring Enhanced and Accurate Lists of (REAL) Health Providers Act), and section 6224 (Modernizing and Ensuring Pharmacy Benefit Manager Accountability) of the Consolidated Appropriations Act, 2026.”

    Checked

  • CMS Proposes Reforms to Strengthen Transparency and Affordability in Medicare Advantage and Part D

    · Centers for Medicare & Medicaid Services

    Centers for Medicare & Medicaid Services states: “The Centers for Medicare & Medicaid Services (CMS) today issued a proposed rule that would improve the accuracy of provider directories for Medicare Advantage plans, establish transparency and compensation requirements for Pharmacy Benefit Managers (PBMs), and deliver enhanced cost-saving protections for low-income Medicare beneficiaries.”

    Checked

  • South Carolina: $167M to Build Rural Care Sites, Upgrade Health Technology & Strengthen Prevention

    · Centers for Medicare & Medicaid Services

    Centers for Medicare & Medicaid Services states: “This federal investment will support telehealth, remote monitoring, mobile care, cybersecurity upgrades, and new technology to improve maternal and behavioral health care. The Trump Administration announced that a $167 million investment is being delivered to expand local access, modernize technology and infrastructure, improve prevention, and strengthen workforce capacity for South Carolinians through the federal Rural Health Transformation Program. This investment will give residents more ways to access primary care, maternal and infant health, pediatrics, wellness, and behavioral health through new and modernized care locations, mobile units, telehealth, and other health care technologies, such as local 24-hour pharmacy kiosks.”

    Checked

More: Pharmacy operations · all standards changes

Talk with IHS's CEO

A 30-minute introductory meeting with Thomas G. Goddard, JD, PhD, to scope what your organization needs.

Schedule a Free Discovery Session